RAS gene therapy (recombinant adenovirus vector)(Kunming University/920th Hospital of Joint Logistics Support Force)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameRAS gene therapy (recombinant adenovirus vector)(Kunming University/920th Hospital of Joint Logistics Support Force)
Drug Alias NamerAd vector-delivered anti-p21Ras scFv( Kunming University/920th Hospital of Joint Logistics Support Force)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Cytokine-induced killer cell
Mechanisms of ActionGTPase Ras modulators
TargetsGTPase Ras
Therapy Area/IndicationsGlioma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaPending
Originator CompaniesKunming University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesKunming UniversityThe 920th Hospital Of Joint Logistics Support Force Of PLA
Active IndicationsN/A
Inactive IndicationsGlioma

Other Information

ATC CodeN/A
Related LinksN/A